NAD+: adverse events during infusions
In Grant and colleagues’ 2019 pilot, eight men received intravenous NAD+ and three received saline. No adverse events were observed during the six-hour infusions. [1]
Reyna and colleagues’ 2026 retrospective study describes different conditions: four days of infusions in a commercial setting. NAD+ recipients reported moderate or severe gastrointestinal symptoms, increased heart rate and chest pressure, resolving after infusion. [2]
Different conditions and small samples prevent generalizing reaction frequencies or establishing safety of a particular reagent batch or other routes. [1,2]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Adverse events during six-hour infusions | Eight men received intravenous NAD+, three received saline (pilot study) | None observed; the small sample and different conditions do not generalize reaction frequencies | [1] |
| Moderate or severe gastrointestinal symptoms | Four days of NAD+ infusions in a commercial setting (retrospective study) | Reported; resolved after infusion; no percentage given | [2] |
| Increased heart rate | The same setting | Reported; resolved after infusion; no frequency given | [2] |
| Chest pressure | The same setting | Reported; resolved after infusion; no frequency given | [2] |
References
- Grant R et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ https://doi.org/10.3389/fnagi.2019.00257.
- Reyna K et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting https://doi.org/10.3389/fragi.2026.1652582.